• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Geodon (ziprasidone HCl) Capsules and Oral Suspension and Geodon (ziprasidone mesylate) Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

July 2013

Summary View

WARNINGS AND PRECAUTIONS

Metabolic Changes
  • Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.
     

 

March 2013

Summary View

WARNINGS AND PRECAUTIONS

Hyperprolactinemia
  • ...Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density.